Eloxx Pharmaceuticals (ELOX) Reports Q1 Loss of $0.31/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Eloxx Pharmaceuticals (ELOX) Reports Q1 Loss of $0.31/Share

Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update

May 10, 2018 4:01 PM EDT

Company on track to initiate Phase 2 clinical trials for investigational drug ELX-02 in cystic fibrosis and cystinosis in 2018 and sufficiently funded to top line data 

Formation of Scientific Advisory Board with expertise in nonsense mutations and nonsense mediated decay

Company to host webcast and conference call on Thursday, May 10, 2018 at 4:30 pm ET

WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Eloxx), (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis,... More